Fibroblastic Stromal Cells Express Receptor Activator of NF-κB Ligand and Support Osteoclast Differentiation
Tóm tắt
Osteoclast formation in bone is supported by osteoblasts expressing receptor activator of NF-κB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) expression. Numerous osteotropic factors regulate expression levels of RANKL and the RANKL decoy receptor osteoprotegerin (OPG) in osteoblasts, thereby affecting osteoclast differentiation. However, not only is RANKL widely expressed in soft tissues, but osteoclasts have been noted in extraskeletal lesions. We found that cultured skin fibroblastic cells express RANKL, M-CSF, and OPG messenger (mRNA). Stimulation by 1α,25 dihydroxyvitamin D3 [1,25(OH)2D3] plus dexamethasone (Dex) augmented RANKL and diminished OPG mRNA expression in fibroblastic cells and caused the formation of numerous osteoclasts in cocultures of skin fibroblastic cells with hemopoietic cells or monocytes. The osteoclasts thus formed expressed tartrate-resistant acid phosphatase (TRAP) and calcitonin (CT) receptors and formed resorption pits in cortical bone. Osteoclast formation also was stimulated (in the presence of Dex) by prostaglandin E2 (PGE2), interleukin-11 (IL-11), IL-1, tumor necrosis factor-α (TNF-α), and parathyroid hormone-related protein (PTHrP), factors which also stimulate osteoclast formation supported by osteoblasts. In addition, granulocyte-macrophage-CSF (GM-CSF), transforming growth factor-β (TGF-β), and OPG inhibited osteoclast formation in skin fibroblastic cell-hemopoietic cell cocultures; CT reduced only osteoclast nuclearity. Fibroblastic stromal cells from other tissues (lung, respiratory diaphragm, spleen, and tumor) also supported osteoclast formation. Thus, RANKL-positive fibroblastic cells in extraskeletal tissues can support osteoclastogenesis if osteolytic factors and osteoclast precursors are present. Such mesenchymally derived cells may play a role in pathological osteolysis and may be involved in osteoclast formation in extraskeletal tissues.
Từ khóa
Tài liệu tham khảo
Suda, 1992, Modulation of osteoclast differentiation, Endocr Rev, 13, 66
Yasuda, 1998, Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL, Proc Natl Acad Sci U S A, 95, 3597, 10.1073/pnas.95.7.3597
Lacey, 1998, Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation, Cell, 93, 165, 10.1016/S0092-8674(00)81569-X
Horwood, 1998, Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells, Endocrinology, 139, 4743, 10.1210/endo.139.11.6433
Kong, 1999, OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis, Nature, 397, 315, 10.1038/16852
Quinn, 1992, Polymethyl-methacrylate-induced inflammatory macrophages resorb bone, J Bone Joint Surg Br, 74, 652, 10.1302/0301-620X.74B5.1527108
Quinn, 1996, Cells of the mononuclear phagocyte series differentiate into osteoclastic lacunar bone resorbing cells, J Pathol, 179, 106, 10.1002/(SICI)1096-9896(199605)179:1<106::AID-PATH535>3.0.CO;2-H
Quinn, 1994, Cellular and hormonal mechanisms associated with malignant bone resorption, Lab Invest, 71, 465
Quinn, 1998, Human tumour-associated macrophages differentiate into osteoclastic bone-resorbing cells, J Pathol, 184, 31, 10.1002/(SICI)1096-9896(199801)184:1<31::AID-PATH962>3.0.CO;2-V
Anderson, 1997, A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function, Nature, 390, 175, 10.1038/36593
Kartsogiannis, 1999, Localization of RANKL (receptor activator of NF-kB ligand) mRNA in skeletal and extraskeletal tissue, Bone, 25, 525, 10.1016/S8756-3282(99)00214-8
Athanasou, 1991, Bone resorption by macrophage polykaryons of giant cell tumour of tendon sheath, Br J Cancer, 63, 527, 10.1038/bjc.1991.125
Athanasou, 1989, The origin and nature of stromal osteoclast-like multinucleated giant cells in breast carcinoma: Implications for tumour osteolysis and macrophage biology, Br J Cancer, 59, 491, 10.1038/bjc.1989.102
Athanasou, 1992, Bone resorption by macrophage polykaryons of a pilar tumor of scalp, Cancer, 70, 469, 10.1002/1097-0142(19920715)70:2<469::AID-CNCR2820700215>3.0.CO;2-0
Neale, 1997, Giant cells in pigmented villo nodular synovitis express an osteoclast phenotype, J Clin Pathol, 50, 605, 10.1136/jcp.50.7.605
Khan, 1997, Atypical fibroxanthoma with osteoclast-like multinucleated giant cells, Am J Dermatopathol, 19, 174, 10.1097/00000372-199704000-00012
Anand, 1994, Characterization of intraocular tumors arising in transgenic mice, Invest Opthalmol Vis Sci, 35, 3533
Udagawa, 1995, Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors, J Exp Med, 182, 1461, 10.1084/jem.182.5.1461
Horwood, 1998, Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor, J Clin Invest, 101, 595, 10.1172/JCI1333
Nicholson, 1986, Abundant calcitonin receptors in isolated rat osteoclasts. Biochemical and autoradiographic characterization, J Clin Invest, 78, 355, 10.1172/JCI112584
Akatsu, 1992, Preparation and characterization of a mouse osteoclast-like multinucleated cell population, J Bone Miner Res, 7, 1297, 10.1002/jbmr.5650071109
Chambers, 1984, Resorption of bone by isolated rabbit osteoclasts, J Cell Sci, 66, 383, 10.1242/jcs.66.1.383
Horwood, 1999, Activated T-lymphocytes support osteoclast formation: A mechanism for rheumatoid arthritis, Biochem Biophys Res Commun, 265, 144, 10.1006/bbrc.1999.1623
Wani, 1999, Prostaglandin E2 co-operates with TRANCE in osteoclast induction from hemopoietic precursors: Synergistic activationn of differentiation, cell spreading, and fusion, Endocrinology, 140, 1927, 10.1210/endo.140.4.6647
Vidal, 1998, Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: Down-regulation by glucocorticoids, J Endocrinol, 159, 191, 10.1677/joe.0.1590191
Dougall, 1999, RANK is essential for osteoclast and lymph node development, Genes Dev, 13, 2412, 10.1101/gad.13.18.2412
Quinn, 1994, Cellular and hormonal factors influencing monocyte differentiation to osteoclastic bone-resorbing cells, Endocrinology, 134, 2416, 10.1210/endo.134.6.8194468
Owens, 1996, Bone cells required for osteoclastic resorption but not for osteoclastic differentiation, Biochem Biophys Res Commun, 222, 225, 10.1006/bbrc.1996.0726
Jimi, 1999, Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function, J Immunol, 163, 434, 10.4049/jimmunol.163.1.434
Chambers, 1985, Bone cells predispose bone surfaces to resorption by exposure of mineral to osteoclastic contact, J Cell Sci, 76, 155, 10.1242/jcs.76.1.155
Hattersley, 1991, Effects of transforming growth factor beta 1 on the regulation of osteoclastic development and function, J Bone Miner Res, 6, 165, 10.1002/jbmr.5650060210